Greg Zante - 28 Jul 2026 Form 4 Insider Report for Viking Therapeutics, Inc. (VKTX)

Reporting relationship: Chief Financial Officer
Issuer ticker: VKTX
Reported as of: 28 Jul 2026
Net transaction value: -$710,141
SEC form: 4
Accepted by SEC: 29 Jul 2026, 20:06:43 UTC
Prior SEC filing: 05 Jan 2026
Source filing: View source filing
Reporting owner signature: /s/ Michael Morneau, as Attorney-in-Fact

Key filing fact

Greg Zante filed Form 4 for Viking Therapeutics, Inc. (VKTX) on 29 Jul 2026.

Key facts

This page summarizes Greg Zante's Form 4 filing for Viking Therapeutics, Inc. (VKTX).
2 reported transactions and 0 derivative rows are listed below.
Accepted by SEC: 29 Jul 2026, 20:06.

Change

Previous filing in this sequence was filed on 05 Jan 2026.
Current net transaction value: -$710,141.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001264949 Primary reporting owner

ZANTE GREG

Relationship: Chief Financial Officer
Address: C/O VIKING THERAPEUTICS, INC., 9920 PACIFIC HEIGHTS BLVD, SUITE 350, SAN DIEGO
Signature: /s/ Michael Morneau, as Attorney-in-Fact
Signature date: 29 Jul 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

VKTX transaction

Common Stock, par value $0.00001 per share

Award

Transaction value
Shares: +31,667
Change %: +16%
Price: $0.000000^*
Shares after: 233,421
Date: 28 Jul 2026
Ownership: Direct
Footnotes: F1, F2

VKTX transaction

Common Stock, par value $0.00001 per share

Sale

Transaction value: $710,141
Shares: -21,217
Change %: -9.1%
Price: $33.47
Shares after: 212,204
Date: 29 Jul 2026
Ownership: Direct
Footnotes: F3, F4

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 4 footnotes

Footnote F1

The reported securities were subject to a performance restricted stock unit award that was granted on January 3, 2023, 33.33% of which vested on July 28, 2026 upon the achievement of a non-financial performance goal.

Footnote F2

Includes 11,055 shares acquired on May 20, 2024 pursuant to the Issuer's 2014 Employee Stock Purchase Plan and 808 shares acquired on May 20, 2026 pursuant to the Issuer's 2024 Employee Stock Purchase Plan

Footnote F3

These shares were automatically sold on a non-discretionary basis solely to satisfy certain tax withholding obligations in connection with the issuance of shares upon the vesting of certain shares of common stock subject to the performance restricted stock unit award described in Footnote 1.

Footnote F4

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $33.30 to $33.805, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in the this footnote.